Bayer

Last updated January 31, 2026

432

Innovation Areas

13,147

Inventors

104

Collaborations

Butaphosphane oxymetazoline co-solvent system: BayerRecent Research Landscape

Oxidative degradation of fluoroquinolones in liquid form compromises shelf-life and therapeutic potency. This formulation leverages specific antioxidant synergies to maintain chemical integrity in aqueous environments.

What technical problems is Bayer addressing in Butaphosphane oxymetazoline co-solvent system?

Uncontrolled drug release rates

(28)evidences

Amorphous compounds and complex co-solvent systems are required when drug molecules fail to dissolve or remain stable in standard carriers. Overcoming low solubility ensures consistent bioavailability and therapeutic efficacy.